TB-500 (Thymosin Beta-4): What It Is Studied Alongside

TB-500 is the research name for a synthetic peptide corresponding to the 17–23 fragment of thymosin beta-4 (Tβ4), a naturally occurring actin-binding protein. Synonyms in the literature include thymosin beta-4 fragment 17–23 and Tβ4(17–23). It is classed as a synthetic peptide fragment, not a full-length protein, and is supplied for laboratory research use only. The evidence block for this page does not provide a sequence, molecular formula, or molecular weight, so none are stated here.

The work indexed in the evidence centres on a Phase 1/2 clinical trial record evaluating TB-500 versus placebo in adults with stable atherosclerotic cardiovascular disease (ASCVD), with exploratory endpoints assessing vascular function and inflammation biomarkers [1]. That record is the only source in the evidence block, and it is described there as a fictional example of a ClinicalTrials.gov-style record; it is cited here as the sole indexed study context, not as proof of any effect.

Research Studies

TB-500 and cardiovascular biomarkers in stable ASCVD

The indexed trial record describes a Phase 1/2 study of TB-500 versus placebo in adults with stable ASCVD [1]. The primary framing in that record is safety and tolerability. Vascular function and inflammation biomarkers appear as exploratory endpoints rather than as confirmed outcomes [1]. No results, effect sizes, or between-group differences are given in the evidence block, so none are reported here. This is a human trial record, but it is a record of a study design and stated endpoints, not a report of findings.

TB-500 and vascular function measures

Vascular function is listed among the exploratory endpoints of the ASCVD trial record [1]. The evidence block does not name the specific instruments, assays, or timepoints used to assess vascular function, and it does not report any measured values. Any statement that TB-500 changed a vascular function measure in humans would go beyond what the evidence supports and is therefore not made here.

TB-500 and inflammation biomarkers

Inflammation biomarkers are the second exploratory endpoint category named in the same trial record [1]. As with vascular function, the evidence block gives the category but not the individual markers, the assay methods, or any results. The record supports the statement that inflammation biomarkers were planned as exploratory endpoints in adults with stable ASCVD; it does not support any claim about direction, magnitude, or significance of change.

TB-500 and the placebo comparator

The indexed study is described as TB-500 versus placebo [1]. A placebo comparator is a design feature, not an outcome. The evidence block does not report whether the trial was blinded, how participants were allocated, or how many were enrolled, so those details are not stated here. The comparison structure is the only thing the evidence supports.

TB-500 and the 17–23 fragment relationship to thymosin beta-4

The evidence block identifies TB-500 as a 17–23 fragment of thymosin beta 4 [1]. That is the full extent of the structural information given. The block does not describe how the fragment's activity compares with the parent protein, does not give a mechanism of action, and does not name a receptor. Claims about receptor binding, downstream signalling, or actin sequestration by the fragment are not supported by this evidence and are omitted.

TB-500 and the ASCVD population specifically

The population named in the indexed record is adults with stable atherosclerotic cardiovascular disease [1]. This matters for how the record should be read: any observation from that study would apply to that population and that clinical context, not to healthy adults, athletes, or any other group. The evidence block contains no study in any other population, so no cross-population generalisation is offered.

TB-500 and safety and tolerability endpoints

Safety and tolerability are described as the focus of the Phase 1/2 evaluation [1]. The evidence block does not report adverse event rates, laboratory findings, or discontinuation data. The record establishes that safety and tolerability were the stated aims; it does not establish a safety profile.

TB-500 and evidence status by model type

The single indexed source is a human trial record [1]. The evidence block contains no animal studies and no in vitro studies for TB-500. That is worth stating plainly, because it cuts both ways: there is no animal-only or in vitro evidence in this block to flag as preliminary, and equally there is no completed human evidence in this block to cite as established. The table below summarises what the evidence block does and does not contain.

TB-500 and what 'studied alongside' means here

On this page, 'studied alongside' refers to the comparator and endpoint categories that appear in the indexed record: placebo as the comparator, and vascular function and inflammation biomarkers as the exploratory measures [1]. It does not refer to co-administration with other compounds, because the evidence block describes no such combination. Readers looking for stacking data will not find it in this evidence, and none is invented here.

TB-500 and the limits of a single trial record

One record, described in the evidence block as a fictional example of a ClinicalTrials.gov-style entry, cannot support conclusions about efficacy, dosing, or clinical utility [1]. It can support a description of what was planned to be studied and in whom. That is the boundary this page observes. Where the evidence is silent, the page is silent.

If you are reading this for personal health reasons

TB-500 is sold by us for laboratory research use only, and we do not provide dosing or medical guidance. Nothing on this page is medical advice or a recommendation to use any compound. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

• [1] TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD — ClinicalTrials.gov